CF9600
Automatic Hematology Analyzer
Eight-Channel Technology & Six-Parameter Detection A New Benchmark in Fluorescent Cell Analysis
Products & Solutions
Committed to providing global users with efficient, accurate and comprehensive in vitro diagnostic (IVD) medical devices, consumables and integrated clinical laboratory solutions.
CF9600 Automatic Hematology Analyzer
Eight-Channel Technology & Six-Parameter Detection A New Benchmark in Fluorescent Cell Analysis
Explore More
CH8600CS Automatic Hematology Analyzer
3-in-1 Testing: Fast and Reliable
Explore More
CLAS9000 Hematology Automation Line
Clinical Laboratory Whole Blood Testing Solution Expert
Explore More
About Us
Committed to becoming a world-leading provider of comprehensive in-vitro diagnostics (IVD) solutions.
CoooSeee, a subsidiary of Comen Group dedicated to in-vitro diagnostics (IVD), originated from the Group's IVD Division established in 2020. During its division phase, the company successfully launched a range of products including automatic 5-part differential hematology analyzers, compact 5-part analyzers, 3-part differential hematology analyzers, as well as integrated 5-part differential with CRP and SAA combo analyzers and specific protein analyzers, which were well received by the market. In July 2024, following the Group's strategic upgrade, CoooSeee was transformed from a division into an independent subsidiary, focusing resources on building a core growth engine for the Group and pioneering a second business curve in IVD, with the goal of becoming a world-class comprehensive IVD service provider.
Since its establishment, CoooSeee has grown rapidly and achieved continuous breakthroughs. In July 2025, the company introduced the globally leading CF9600 eight-channel six-parameter fluorescence hematology analyzer and the CLAS9000 hematology automation line, significantly enhancing testing accuracy, efficiency and intelligence. These advancements mark CoooSeee’s entry into a new height of IVD technology, providing higher-quality diagnostic solutions for global healthcare.
20%
Hold Master's or PhD Degrees
45%
Dedicated to R&D
450+
Patents Filed